Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of estradiol-17 beta on the activities of glycolytic enzymes from female rat brain was studied. The following enzymes were examined:
hexokinase
(HK, EC 2.7.1.1), phosphofructokinase (PFK, EC 2.7.1.11), aldolase (EC 4.1.2.13), glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12), phosphoglycerate kinase (EC 2.7.2.3), phosphoglycerate mutase (EC 2.7.5.3), enolase (EC 4.2.1.11) and pyruvate kinase (PK, EC 2.7.1.40). The activities of HK (soluble and membrane-bound), PFK and PK were increased after 4 h of hormone treatment, while the others remained constant. The changes in activity were not seen in the presence of actinomycin D. The significant rise of the activities of the key glycolytic enzymes was also observed in the cell culture of mouse
neuroblastoma
C1300 treated with hormone. Only three of the studied isozymes, namely, HKII, B4 and K4 were found to be estradiol-sensitive for HK, PFK and PK, respectively. The results obtained suggest that rat brain glycolysis regulation by estradiol is carried out in neurons due to definite isozymes induction.
...
PMID:Rat brain glycolysis regulation by estradiol-17 beta. 153 2
Exposure to the pentobarbital potently inhibited the 2-deoxy glucose uptake in cultured
neuroblastoma
cells. The inhibition was assumed to be due to saturation of the uptake in the early stage where the incorporation was linear in the nontreated cells. On the contrary, the incorporation of 3-O-methyl glucose, another glucose analog which is not phosphorylated by
hexokinase
, was not altered by the treatment with pentobarbital. These results suggest that the suppression of
hexokinase
is involved in the above-mentioned effect of pentobarbital.
...
PMID:Barbiturates suppress glucose utilization by inhibition of hexokinase in neuroblastoma cells. 157 41
This improved isotope-dilution gas chromatographic/mass spectrometric (GC/MS) method, in which [13C]glucose is the internal standard, meets the requirements of a Definitive Method. In a first study with five reconstituted lyophilized sera, a nested analysis of variance of GC/MS values indicated considerable among-vial variation. The CV for 32 measurements per serum ranged from 0.5 to 0.9%. However, concentration and uncertainty values (mmol/L per gram of serum) assigned to one serum by the
NBS
Definitive Method (7.56 +/- 0.28) were practically identical to those obtained with the proposed method (7.57 +/- 0.20). In the second study, we used twice more [13C]glucose diluent to assay four serum pools and two lyophilized sera. The CV ranged from 0.26 to 0.5% for the serum pools and from 0.28 to 0.59% for the lyophilized sera. In comparison, results by the
hexokinase
/glucose-6-phosphate dehydrogenase reference method agreed within acceptable limits with those by the Definitive Method but tended to be slightly higher (up to 3%) for lyophilized serum samples or slightly lower (up to 2.5%) for serum pools.
...
PMID:Precision of glucose measurements in control sera by isotope dilution/mass spectrometry: proposed definitive method compared with a reference method. 330 Oct 68
Cultured
neuroblastoma
cells (clone neuro-2a) were used to demonstrate the influence of an anesthetic on energy metabolism by acting on the intracellular distribution of
hexokinase
activity. First of all, there was to be shown that a relationship between the intracellular
hexokinase
distribution and energy metabolism actually exists in
neuroblastoma
cells. Since glucose-6-phosphate could be assumed to be the main regulator of this enzyme distribution, experimental conditions were chosen where the glucose-6-phosphate level was changed significantly. A decrease in the glucose-6-phosphate level in the cells was achieved by deprivation of glucose and oxygen for 30 min. Under these conditions the glucose-6-phosphate level and the soluble
hexokinase
activity decreased significantly. The effect was reversible when glucose and oxygen were again added to the incubation medium of the cells. On the other hand, the antimetabolite 6-aminonicotinamide produced an accumulation of glucose-6-phosphate which caused an increase in the soluble
hexokinase
activity. These results brought evidence for a correlation of intracellular
hexokinase
distribution and energy metabolism. When alpha-(+/-)-5-allyl-1-methyl-5-(1-methyl-2-pentinyl) barbituric acid (methohexital) was added to the incubation medium of the
neuroblastoma
cells, a dose-dependent increase in soluble
hexokinase
activity was measurable, whereas the glucose-6-phosphate level was decreased at least within a therapeutically relevant dosage range of the anesthetic. This effect was reversible when methohexital was washed out from the cells.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Effect of methohexital on the relationship between hexokinase distribution and energy metabolism in neuroblastoma cells. 359 43
In this study pyruvate kinase,
hexokinase
and aldolase are investigated in two types of embryonal tumors, neuroblastomas and medulloblastomas; the results are compared with similar studies in gliomas. The activities of
hexokinase
and pyruvate kinase are significantly decreased in neuroblastomas. In
neuroblastoma
and medulloblastoma all five forms of pyruvate kinase (K4, K3M, K2M2, KM3 and M4) are present. In contrast, the gliomas investigated are characterized by the presence of mainly K4 and a little K3M. In neuroblastomas, medulloblastomas and gliomas,
hexokinase
type I is present; in addition,
hexokinase
type II is present in two medulloblastomas. Aldolase A is the predominant isozyme in all tumors investigated; this is in contrast with normal nervous tissue. It can be concluded that the isozyme characteristics especially of pyruvate kinase from neuroblastomas and medulloblastomas are comparable with similar findings in retinoblastoma; these findings support the hypothesis that these three tumors have a common embryonic origin.
...
PMID:Glycolytic enzymes from human neuroectodermal tumors of childhood. 632 86
In thiopental anesthesia of rats cerebral mitochondrial
hexokinase
activity was solubilized. This solubilization was also observed when the period necessary for the removal of the rat brain was shortened to 15 s by brain blowing. The influence of the drug on the binding of
hexokinase
activity to mitochondria of brain, liver and
neuroblastoma
cells was studied in vitro. Solubilization of
hexokinase
activity was achieved in all systems at therapeutically relevant thiopental concentrations. On the other hand, chlorpromazine as a highly lipophilic drug only solubilized
hexokinase
activity at concentrations being already lytic to the membrane. Thus, it is concluded that thiopental solubilize
hexokinase
activity by affecting the mitochondrial membrane, and that this effect is not only dependent on the lipophilic character of a drug.
...
PMID:Solubilization of hexokinase activity by an effect of thiopental on the mitochondrial membrane. 707 Nov 27
In earlier work it has been shown that mitochondrially bound brain
hexokinase
is solubilized by anesthetics. This effect was reevaluated using cultured cells. For the present experiments Ehrlich ascites, Harding-Passey melanoma, C-1300-
neuroblastoma
and C-6-glioma cells were used. The great portion of
hexokinase
activity bound to the mitochondria of these cells was similar to that in rat brain. After incubation with thiopental the soluble
hexokinase
activity was increased in all cells studied. Using
neuroblastoma
and glioma cells the thiopental effect was demonstrated to be dose-dependent. Thus, cultured tumor cells seem to be useful for studying the relationship of the intracellular distribution of
hexokinase
activity, energy metabolism and the effect of anesthetics.
...
PMID:Influence of thiopental on intracellular distribution of hexokinase activity in various tumor cells. 719 88
Rasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor which has been developed as an anti-Parkinson drug. In controlled monotherapy and as adjunct to L-dopa it has shown anti-Parkinson activity. In cell culture (PC-12 and
neuroblastoma
SH-SY5Y cells) it exhibits neuroprotective and anti-apoptotic activity against several neurotoxins (SIN-1, MPTP, 6-hydroxydopamine and N-methyl-(R)-salsolinol) and ischemia. In vivo, it reduces the sequelae of traumatic brain injury in mice and speeds their recovery. The neuroprotective activity of rasagaline does not result from MAO B inhibition, since its S-enantiomer, TVP1022, which has 1000-fold weaker MAO inhibitory activity, exhibits similar neuroprotective properties. Introduction of a carbamate moiety into the rasagiline molecule to confer cholinesterase inhibitory activity for the treatment of Alzheimer's disease, resulted in compounds TV3326 [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] and its S-enantiomer TV3279 [(N-Propargyl-(3S)Aminoindan-5-YL)-Ethyl Methyl Carbamate], which retain the neuroprotective activities of rasagiline and TVP1022. They also antagonize scopolamine-induced impairments in spatial memory. In addition, TV3326 exhibits brain-selective MAO A and B inhibitory activity after chronic administration and has antidepressant-like activity in the forced swim test. This is associated with an increase in brain levels of serotonin. The anti-apoptotic activity of these propargylamine-containing derivatives may be related to their ability to delay the opening of voltage-dependent anion channels (VDAC), which are part of the mitochondrial permeability transition pore. The propargylamine moiety is responsible for the increase in the mitochondrial family of Bcl-2 proteins, prevention in the fall in mitochondrial membrane potential, prevention of the activation of caspase 3, and of translocation of glyceraldehyde-3-phosphate dehydrogenase from the cytoplasm to the nucleus. The latter processes are closely associated with neurotoxin-induced apoptosis. Rasagiline interacts with and prevents the binding of PKI 1195 to the pro-apoptotic peripheral benzodiazepine receptor, which together with Bcl-2,
hexokinase
, porin, and adenine nucleotide translocator constitutes part of the VDAC. Furthermore, rasagiline, TV3326 and TV3279 are able to influence the processing of amyloid precursor protein by activation of alpha-secretase and increasing the release of soluble alpha APP in rat PC-12 and human
neuroblastoma
SH-SY5Y cells and in rat and mice cortex and hippocampus. This process has been shown to involve the upregulation of PKC and MAP kinase. It is quite likely that the induction of Bcl-2 and activation of PKC by rasagiline and TV3326 is closely linked to the anti-apoptotic action of these drugs and their ability to process APP by activation of alpha-secretase.
...
PMID:Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. 1204 33
An easy and fast method for the quantitative analysis of nucleotides by capillary zone electrophoresis was developed. The method employing a neutral-bonded capillary and reversed polarity mode provided a good resolution and a short analysis time of less than 5 min. The samples were injected electrokinetically using -6 kV voltage for 30 s and detected by their UV absorbance at 254 nm. Constant current (-45 microA) was applied, and a phosphate buffer, pH 7.4, was used. The detection limits for ATP, UDP, and UTP ranged between 0.14 and 0.28 microM. This method was required for the investigation of the purity of the commercially available nucleotides used in pharmacological studies. In addition, the analytical method was applied to study the metabolism of nucleotides in a cell line,
neuroblastoma
x glioma hybrid cells (NG108-15), which is used in pharmacological studies with nucleotides, since it contains purine- and pyrimidine-sensitive nucleotide receptors. Furthermore, we used the new method for monitoring enzymatic studies using the enzyme
hexokinase
to convert nucleotide triphosphates to diphosphates.
...
PMID:Fast, efficient capillary electrophoresis method for measuring nucleotide degradation and metabolism. 1206 39
Manganese (Mn) is a trace metal required for normal growth and development. Manganese neurotoxicity is rare and usually associated with occupational exposures. However, the cellular and molecular mechanisms underlying Mn toxicity are still elusive. In rats chronically exposed to Mn, their brain regional Mn levels increase in a dose-related manner. Brain Mn preferentially accumulates in mitochondria; this accumulation is further enhanced with Mn treatment in vivo. Exposure of mitochondria to Mn in vitro leads to uncoupling of oxidative phosphorylation. These observations prompted us to investigate the hypothesis that Mn induces alterations in energy metabolism in neural cells by interfering with the activities of various glycolytic and TCA cycle enzymes using human
neuroblastoma
(SK-N-SH) and astrocytoma (U87) cells. Treatments of SK-N-SH and U87 cells with MnCl2 induced cell death in these cells, in a concentration- and time-dependent manner, as determined by MTT assays. In parallel with the Mn-induced, dose-dependent decrease in cell survival, treatment of these cells with 0.01 to 4.0 mM MnCl2 for 48 h also induced dose-related decreases in their activities of
hexokinase
, pyruvate kinase, lactate dehydrogenase, citrate synthase, and malate dehydrogenase. Hexokinase in SK-N-SH cells was the most affected by Mn treatments, even at the lower range of concentrations. Mn treatment of SK-N-SH cells affected pyruvate kinase and citrate synthase to a lesser extent as compared to its effect on other enzymes investigated. However, citrate synthase and pyruvate kinase in U87 cells were more vulnerable than other enzymes investigated to the effects of Mn. The results suggest the two cell types exhibited differential susceptibility toward the Mn-induced effects. Additionally, the results may have significant implications in flux control because HK is the first and highly regulated enzyme in brain glycolysis. Thus these results are consistent with our hypothesis and may have pathophysiological implications in the mechanisms underlying Mn neurotoxicity.
...
PMID:Differential lowering by manganese treatment of activities of glycolytic and tricarboxylic acid (TCA) cycle enzymes investigated in neuroblastoma and astrocytoma cells is associated with manganese-induced cell death. 1509 32
1
2
Next >>